Accelerating medicines partnership: Alzheimer's disease (AMP-AD) knowledge portal aids Alzheimer's drug discovery through open data sharing. Expert Opin Ther Targets. 2016;20(4):389-91.R. J. Hodes and N. Buckho
The Accelerating Medicines Partnership®Schizophrenia (AMP®SCZ) was established in 2020 to achieve these aims10,11. The AMP program was initiated by Francis Collins in 2014, then director of the National Institutes of Health (NIH). He went before Congress to create an unprecedented public-priv...
Accelerating Medicines Partnership: Parkinson’s Disease. Genetic Resource. Mov. Disord. 36, 1795–1804 (2021). Article CAS PubMed PubMed Central Google Scholar GA4GH and the International Neuroinformatics Coordinating Facility (INCF) launch community focused on neuroscience data interoperability, https...
This paper outlines the design of the digital component of the Accelerating Medicines Partnership Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year ...
AstraZeneca US is driven by our purpose to deliver life-changing medicines to all patients, yet systemic barriers prevent millions of Americans from achieving their best possible health outcomes. As part of our global sustainability efforts, in 2021 we created Accelerate Change Together (ACT) on ...
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and collaborative drug discovery efforts took place in academia and industry, culminating in several therapeutics being discovered, approved and deployed in a 2-year time frame. Thi
European Medicines Agency ICH S5 (R3) guideline on reproductive toxicology: Detection of toxicity to reproduction for human pharmaceuticals - step 5 EMA, Amsterdam (2020) Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s5-r3-guideline-reproductive-toxicology-detection...
Objectives: The Accelerating Medicines Partnership Parkinson's Disease program has developed a research platform for Parkinson's disease (PD) that integrates the storage and analysis of whole-genome sequencing data, RNA expression data, and clinical data, harmonized across multiple cohort studies. ...
Accelerating Medicines Partnership (AMP)Foundation for the National Institute of Health (FNIH)Advancing the understanding of adeno-associated virus (AAV) biology to human gene therapy has been identified as a critical pre-competitive area that could benefit from a focused public-private partnership. A...
Introduction Target selection and validation Clinically validated targets Targets with chemical probe validation Targets with genetic evidence Medicinal chemistry Cell culture models Animal models Human viral challenge models Pre-empting resistance Concluding remarks 1Centre for Medicines Discovery, Nuffield ...